12:00 AM
 | 
Apr 12, 2004
 |  BC Week In Review  |  Company News  |  Deals

AdProTech, Inflazyme, Avant deal

IZP will acquire Adprotech in a stock deal worth about C$20 million (US$15.2 million). IZP will issue 12.7 million shares at about C$1.59, based on IZP's 15-day closing average prior to the deal. The deal provides IZP with an inflammation technology platform in complement inhibition, and Adprotech's Prodaptin...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >